Impact of BCR-ABL <10% at 6 Months on Outcome of Patients with CML with a Poor Response at 3 Months


Impact of BCR-ABL <10% at 6 Months on Outcome of Patients with CML with a Poor Response at 3 Months
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Jorge E Cortes, MD (1/24/14)
Branford S et al. Any BCR-ABL reduction below 10% at 6 months of therapy significantly improves outcome for CML patients with a poor response at 3 months. Proc ASH 2013;Abstract 254.

Dr Cortes is Deputy Chairman and Section Chief of AML and CML in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.